Table 3 Logistic regression analyses of variables associated with dispensed ADHD medication and OAT
2015 | 2016 | 2017 | ||||
|---|---|---|---|---|---|---|
Dispensed ADHD medication | N = 274 | N = 312 | N = 349 | |||
Not dispensed ADHD medication | N = 7546 | N = 7378 | N = 7236 | |||
Crude OR | Adjusted OR (95% CI) | Crude OR | Adjusted OR (95% CI) | Crude OR | Adjusted OR (95% CI) | |
Age | ||||||
- ≤ 25 | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) |
- 26–35 | 1.8 | 1.8 (0.7–4.5) | 1.3 | 1.3 (0.6–2.9) | 0.8 | 0.8 (0.4–1.7) |
- 36–45 | 1.4 | 1.5 (0.6–2.7) | 0.9 | 1.0 (0.5–2.2) | 0.7 | 0.7 (0.4–1.5) |
- 46–55 | 0.9 | 1.0 (0.4–2.6) | 0.6 | 0.7 (0.3–1.6) | 0.5 | 0.5 (0.2–1.0) |
- ≥ 56 | 0.4 | 0.5 (0.2–1.4) | 0.3 | 0.4 (0.2–0.9) | 0.3 | 0.3 (0.1–0.6) |
Gender | ||||||
- Female | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) |
- Male | 1.1 | 1.0 (0.8–1.4) | 1.1 | 1.0 (0.8–1.3) | 1.2 | 1.2 (1.0–1.6) |
The number of dispensations of OAT opioids per calendar year | ||||||
- ≥ 52 | 1.0 (ref.) | 1.0 (ref.) | 1.00 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.00 (ref.) |
- 13–51 | 0.9 | 1.0 (0.7–1.4) | 0.7 | 0.8 (0.6–1.2) | 1.1 | 1.1 (0.8–1.7) |
- 7–12 | 0.7 | 0.8 (0.5–1.3) | 0.8 | 0.9 (0.6–1.3) | 1.3 | 1.3 (0.9–2.0) |
- 1–6 | 0.7 | 0.7 (0.4–1.2) | 0.9 | 1.0 (0.7–1.6) | 1.0 | 1.0 (0.6–1.7) |
OAT opioidsa | ||||||
- Methadone (incl. Levomethadone) | 1.0 (ref.) | 1.00 (ref.) | 1.00 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) |
- Buprenorphine (incl. combinations) | 2.0 | 1.7 (1.3–2.3) | 2.2 | 1.9 (1.4–2.5) | 1.9 | 1.6 (1.3–2.1) |
Dispensed opioids (excl. OAT opioids) | 1.0 | 1.1 (0.8–1.5) | 1.0 | 1.1 (0.8–1.5) | 1.4 | 1.5 (1.1–1.9) |
Dispensed gabapentinoids | 0.8 | 0.9 (0.5–1.4) | 1.2 | 1.2 (0.8–1.7) | 1.1 | 1.0 (0.7–1.4) |
Dispensed benzodiazepines and/or z-hypnotics | 0.8 | 1.0 (0.7–1.2) | 0.8 | 0.9 (0.7–1.2) | 1.0 | 1.0 (0.8–1.3) |
Dispensed DAA | 0.8 | 1.0 (0.5–2.1) | 1.1 | 1.4 (0.9–2.3) | 1.4 | 1.6 (1.2–2.2) |